do not combine glp-1 receptor agonists with dpp-4 inhibitors guideline Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology Complete pharmacology and pharmacotherapy of

GLP-1 medications are everywhere these days especially online

Metabolic endotoxemia initiates obesity and insulin resistance

Unfortunately, numerous psychotropic medications can increase weight and appetite due to a variety of mechanisms, including antihistaminergic effects, direct appetite-stimulating effects, and proclivities to cause insulin resistance

While there is mixed evidence regarding whether GLP-1RA increase risk for acute pancreatitis and they are associated with thyroid tumors in animals, prescribers should consider these possible adverse effects in patients at elevated risk for either outcome

Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review